Covid Vaccine Front-Runner Is Months Ahead of Her Competition

The University of Oxford candidate, led by Sarah Gilbert, might be through human trials in September. AstraZeneca has lined up agreements to produce 2 billion doses. Could this be the one?

Sarah Gilbert

Sarah Gilbert

Photographer: John Cairns/University of Oxford

In April, Sarah Gilbert’s three children, 21-year-old triplets all studying biochemistry, decided to take part in a trial for an experimental vaccine against Covid-19.

It was their mother’s vaccine—she leads the University of Oxford team that developed it—but there wasn’t a big family talk. “We didn’t really discuss it as I wasn’t home much at the time,” Gilbert told me recently. She’d been working around the clock, as one does while trying to end a pandemic, and at any rate wasn’t worried for her kids. “We know the adverse event profile and we know the dose to use, because we’ve done this so many times before,” she says. “Obviously we’re doing safety testing, but we’re not concerned.”